

AD_____

Award Number: W81XWH-05-1-0276

TITLE: Immune Suppression and Inflammation in the Progression of Breast Cancer

PRINCIPAL INVESTIGATOR: Stephanie K. Bunt

CONTRACTING ORGANIZATION: The University of Maryland Baltimore County
Baltimore, Maryland 21250-0001

REPORT DATE: March 2006

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) March 2006		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 25 Feb 05 – 24 Feb 06	
Immune Suppression and Inflammation in the Progression of Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-05-1-0276	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Stephanie K. Bunt E-mail: stephw1@umbc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Maryland Baltimore County Baltimore, Maryland 21250-0001				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Epidemiological and experimental observations support the hypothesis that chronic inflammation contributes to the development and progression of cancers; however the mechanisms underlying the relationship between inflammation and breast cancer are poorly understood. To study these mechanisms we have used an experimental mouse system in which 4T1 mammary carcinoma cells constitutively express the pro-inflammatory cytokine, IL-1 β , resulting in an inflammatory microenvironment at the tumor site. Our results confirm the hypothesis that a pro-inflammatory microenvironment enhances tumor progression. More importantly, they suggest a novel mechanism by which inflammation facilitates tumor growth. We find that mice with IL-1 β -producing tumors have in their spleens elevated levels of immature myeloid-derived cells with a Gr1+CD11b+ phenotype, which inhibit the activation of CD4+ and CD8+ T lymphocytes. Similar cells, termed myeloid suppressor cells, are frequently present in patients and experimental animals with tumors. These findings suggest that inflammation may promote malignancy by producing pro-inflammatory cytokines, such as IL-1 β , that enhance systemic immune suppression through the induction of myeloid suppressor cells, thereby counteracting immune surveillance and allowing the outgrowth and proliferation of transformed cells.					
15. Subject Terms (keywords previously assigned to proposal abstract or terms which apply to this award) Inflammation, Tumor Immunology, Immune Suppression, Interleukin-1beta, Myeloid Suppressor Cells					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 19	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4-8
Key Research Accomplishments.....	10
Reportable Outcomes.....	10
Conclusions.....	10-11
References.....	11-12
Appendices.....	12

Introduction

The concept that chronic inflammation promotes tumor progression was originally proposed by Virchow in the late 1800's (1). Epidemiological and experimental observations support the hypothesis that chronic inflammation contributes to the development and progression of cancers (1-4); however the mechanisms underlying the relationship between inflammation and breast cancer are poorly understood. Inflammatory components have been shown i) to induce DNA damage which contributes to genetic instability and transformed cell proliferation (1); ii) to promote angiogenesis and thereby enhance tumor growth and invasiveness (4); and iii) to impair myelopoiesis and hematopoiesis thereby causing immune dysfunction and inhibiting immune surveillance (5, 6). Although it is generally accepted that inflammation enhances tumor progression (1, 4, 7), the mechanisms by which inflammation mediates its effects are not well understood.

To study these mechanisms we have developed an experimental system in which tumors constitutively express the pro-inflammatory cytokine, interleukin 1 β (IL-1 β), resulting in an inflammatory microenvironment at the tumor site. We have used IL-1 β because it is a key cytokine in mediating an inflammatory response (8) and has been previously shown to promote primary tumor growth (8-11) and to enhance metastatic disease (11-13). The spontaneously metastatic BALB/c-derived 4T1 mammary carcinoma (14-16) was used because breast cancer is one of the cancers for which inflammation is associated with poor prognosis (6), and because we want to study the effects of inflammation on the progression of both primary and metastatic tumor.

In addition to confirming the concept that a pro-inflammatory microenvironment enhances tumor progression, our results suggest a novel mechanism by which inflammation facilitates tumor growth. We find that IL-1 β -producing tumor cells are potent inducers of a population of immature Gr1⁺CD11b⁺ myeloid-derived cells called myeloid suppressor cells (MSC). Elevated levels of MSC are frequently found in many cancer patients where they cause a global and profound immune suppression (5, 6, 17-20). The finding that IL-1 β up-regulates MSC accumulation in tumor-bearing mice has led us to propose the following causal relationship linking chronic inflammation with tumor progression: As tumor cells proliferate they induce an inflammatory microenvironment consisting of IL-1 β and other pro-inflammatory mediators. The persistence of these mediators causes the accumulation and retention of MSC. The MSC, in turn, initiate and maintain an immune suppressive state which blocks immune surveillance, thereby facilitating the survival and proliferation of transformed cells.

Body

Note: Text appearing in the original statement of work (SOW) is underlined.

Task 1: Phenotypic characterization of IL-1 β induced MSC.

- Create stable 4T1 cell lines which secrete mature IL-1 β (4T1/IL-1 β) by transduction with IL-1 β retrovirus. **Previously Completed**
- Quantify IL-1 β secretion of 4T1 stable transductants by ELISA. **Previously Completed**
- Phenotype the populations of MSCs from 4T1 and 4T1/IL-1 β inoculated mice by flow cytometry using antibodies to surface markers.

Results: 4T1 mammary carcinoma cells were transduced with a retrovirus containing the mature form of hIL-1 β fused to the signal sequence of the IL-1 α to create 4T1/IL-1 β cells. 4T1/IL-1 β cells had similar in vitro growth kinetics to the parental 4T1 cells and secreted 1000pg/ml/5x10⁵/24 hr as quantified by ELISA. 4T1 and 4T1/IL-1 β cells were inoculated into syngeneic BALB/c mice and MSC were purified to examine phenotypic differences between populations. As shown in Figure 1, the expression of various cell surface markers were examined by flow cytometry. 4T1/IL-1 β cells expressed higher levels of CD8, CD80, CD83, and CD14, and lower levels of CD44 and B220 relative to 4T1 MSC. These phenotypic differences suggest that IL-1 β secretion from the 4T1 tumor may be inducing a novel subpopulation of MSC.





Figure 1. MSC from mice with 4T1/IL-1 β tumors and MSC from mice with 4T1 tumors have phenotypic differences. BALB/c mice were inoculated with 4T1 or 4T1/IL-1 β tumor cells and spleens were harvested when tumor diameters reached 8-10mm. MACS purified (>90%) MSC were phenotyped with mAbs to the indicated markers. Dotted peaks are controls (fluorescently labeled soybean protein for IL-1R panel or anti-rat isotype-FITC and anti-rat isotype-PE antibodies for all other panels; 4T1 and 4T1/IL-1 β MSC had the same fluorescent staining for controls, hence only one peak is shown); black solid lines and gray peaks are MSC from 4T1 and 4T1/IL-1 β inoculated mice, respectively.

Final Result for Task 1 -- Completed

Task 2: Functional characterization of IL-1 β induced MSC and determination of target cells which are suppressed by MSC.

- Perform proliferation assays to determine whether MSCs suppress CD4⁺ and/or CD8⁺ T cells. OVA-specific DO11.10 transgenic T cells or HA-specific transgenic T cells will be plated with specific peptide and MSCs from 4T1 and 4T1/IL-1 β inoculated mice. T cell proliferation will be measured with ³H thymidine.
- Perform proliferation assays (Task 2a) with inhibitors of reactive species, Nor-NOHA and L-NMMA, to identify the functional molecule responsible for suppression.
- Measure ROS expression in MSCs from 4T1 and 4T1/IL-1 β inoculated mice by flow cytometry using a fluorescent dye (DCFDA).

Results: As 4T1/IL-1 β MSC are phenotypically distinct from 4T1 MSC, we evaluated whether the 4T1/IL-1 β MSC are also functionally distinct. Previous studies demonstrate that 4T1 MSC suppress both CD4⁺ and CD8⁺ T cells via arginase-dependent mechanisms (21). To test for suppressive differences between 4T1 and 4T1/IL-1 β MSC, CD4⁺ T cell proliferation using OVA-specific DO11.10 transgenic T cells or CD8⁺ T cells proliferation using HA-specific transgenic T cells was measured by ³H thymidine. Transgenic T cells were incubated with specific peptide and purified 4T1 MSC or 4T1/IL-1 β MSC in the presence or absence of inhibitors to arginase and nitric oxide, nor-NOHA and L-NMMA, respectively. In Figure 2A, both 4T1 and 4T1/IL-1 β MSC suppress CD4⁺ T cell proliferation partially through an arginase-dependent mechanism. Figure 2B demonstrates that 4T1/IL-1 β MSC are more suppressive on a per cell basis towards CD8⁺ T cells than 4T1 MSC. Addition of the arginase inhibitor nor-NOHA partially reverses 4T1 MSC suppression but does not reverse suppression by 4T1/IL-1 β MSC indicating that these MSC suppress CD8⁺ T cells through an arginase-independent mechanism. ROS expression by 4T1 and 4T1/IL-1 β MSC was measured by flow cytometry using a fluorescent dye, DCFDA. Figure 2C shows ROS expression by purified 4T1 and 4T1/IL-1 β MSC and indicates that 4T1/IL-1 β MSC produce increased levels of ROS compared to 4T1 MSC, and that a significant amount of this ROS production is arginase-dependent. These experiments suggest that 4T1/IL-1 β MSC are more suppressive towards CD8⁺ T cells and function via a different mechanism.






Figure 2: MSC from mice with 4T1/IL-1 β tumors express increased levels of ROS and suppress CD4⁺ and CD8⁺ T cells. CD4⁺ DO11.10 (A) or CD8⁺ Clone 4 (B) transgenic splenocytes were stimulated with OVA₃₂₃₋₃₃₉ or HA₅₁₈₋₅₂₆ peptide, respectively, and co-cultured in the presence or absence of MACS-purified MSC from mice with 4T1 or 4T1/IL-1 β tumors. Inhibitors of arginase (nor-NOHA), nitric oxide (L-NMMA), or the inactive enantiomer (D-NMMA) were added to some wells. T cell proliferation was measured as c.p.m. of ³H-thymidine. In panels A and B nor-NOHA-treated groups are statistically significantly different from their untreated counterparts at p<0.05. In panel B, nor-NOHA-treated 4T1 MSC are also statistically significantly different from nor-NOHA-treated 4T1/IL-1 β MSC at p<0.05 (C) MACS purified MSC from mice with 4T1 or 4T1/IL-1 β tumors were incubated with DCFDA in the presence or absence of the arginase inhibitor nor-NOHA and ROS production was measured by flow cytometry.

Final Result for Task 2 -- Completed

Task 3: Determine if IL-1 β directly stimulates the accumulation of MSC.

- a. Determine the expression of IL-1 receptor on the surface of MSC by flow cytometry using an antibody to the IL-1R Type 1.

Results: MSC from 4T1/IL-1 β tumor-bearing mice are phenotypically and functionally distinct from 4T1 MSC. To determine if tumor-secreted IL-1 β acts directly on the accumulation and/or quality of MSC, we examined the surface expression of the IL-1R Type I (Figure 1). Neither parental 4T1 nor 4T1/IL-1 β cells express the IL-1 receptor Type I indicating that these cells cannot respond directly to tumor-secreted IL-1 β . These results implicate intermediate cells and/or effector molecules.

Final Result for Task 3 -- Completed

Task 4: Test cytokines downstream if IL-1 β for their ability to induce MSC accumulation.

- a. Analyze the sera and dissociated tumor tissue from 4T1 and 4T1/IL-1 β inoculated mice, by ELISA, for expression of cytokines (IL-1 β , IL-6, IL-10, VEGF).

Results: Serum and dissociated tumor tissue were analyzed for expression of IL-1 β by ELISA. No IL-1 β was detected in the serum of 4T1 or 4T1/IL-1 β inoculated mice, while

IL-1 β was detectable (pg/ml) in dissociated tumor tissue from 4T1/IL-1 β inoculated mice. The lack of detectable IL-1 β in the serum suggests that IL-1 β secretion is a localized event rather than a systemic one. The rest of Task 4 has not been attempted yet.

Task 5: Determine if macrophages are involved in MSC accumulation.

Has not been attempted yet.

Task 6: Determine if IL-1 β secretion and/or inflammation are associated with tumor progression in NeuT spontaneous mammary carcinoma model.

Has not been attempted yet.

Task 7: Determine if blocking inflammatory responses prevents, delays, or minimizes tumor progression.

Has not been attempted yet.

Additional work

While pursuing the above experiments, additional experiments were performed to evaluate whether the effects of IL-1 β on tumor growth and MSC accumulation were dependent on host T cells, B cells or NKT cells. 4T1 and 4T1/IL- β cells were inoculated into immunodeficient nude and RAG2^{-/-} mice, and tumor growth and MSC levels were measured. As determined previously, 4T1/IL-1 β tumors grow significantly faster in BALB/c mice and lead to elevated levels of MSC. Similarly, 4T1/IL-1 β tumors grow significantly faster than 4T1 tumors in RAG2^{-/-} mice indicating that the IL-1 β -induced tumor growth is independent of T cells, B cells, or NKT cells (Figure 3). MSC levels were significantly elevated in both nude and RAG2^{-/-} mice inoculated with 4T1/IL-1 β compared to 4T1, indicating that the IL-1 β increase in MSC accumulation is also independent of T cells, B cells, or NKT cells.




Figure 3. T, B and NKT cells are not required for the IL-1 β -induced accumulation of MSC. BALB/c and RAG2^{-/-} mice were inoculated with 4T1 or 4T1/IL-1 β tumor cells

and monitored for primary tumor growth and survival. (A) Primary tumor diameter plotted as a function of time after tumor inoculation. Growth of primary 4T1/IL-1 β tumors is more rapid than growth of primary 4T1 tumors in both strains ($p < 0.01$). (C) BALB/c, nude and RAG2 $^{-/-}$ mice bearing 4T1 or 4T1/IL-1 β tumors were euthanized at week 5 and the percentage of splenic MSC was quantified by flow cytometry. All columns are statistically significantly different from other columns in the same strain and other strains (including RAG2 $^{-/-}$ with 4T1 vs. RAG2 $^{-/-}$ with 4T1/IL-1 β) at $p < 0.01$ except BALB/c with 4T1 vs. nude with 4T1 and BALB/c with 4T1/IL-1 β vs. nude with 4T1/IL-1 β .

Surgical excision of 4T1 primary tumors from BALB/c mice leads to a partial regression in splenic MSC levels (21). To determine if IL-1 β affects this regression, BALB/c mice were inoculated with 4T1 or 4T1/IL-1 β cells, and primary tumors were either left in place (non-surgery group) or removed (surgery group). In contrast to 4T1 tumor-bearing mice, there was no significant decrease in MSC in mice with resected 4T1/IL-1 β tumors (Figure 4). These results imply that secretion of IL-1 β by the primary tumor either irreversibly enhances MSC accumulation, or the presence of residual IL-1 β prevents the regression of MSC.




Figure 4. MSC do not regress after surgical resection of primary 4T1/IL-1 β tumors. BALB/c mice were inoculated with 4T1 or 4T1/IL-1 β tumor cells and the primary tumors were either left intact (non-surgery groups) or surgically excised (surgery groups). The percent of splenic MSCs was quantified by flow cytometry.

Future Directions

We wish to extend these experiments to IL-1R deficient BALB/c mice (IL-1R $^{-/-}$) which we have recently acquired to determine whether IL-1 β is essential for the accumulation of MSC or whether IL-1 β functions primarily in defining the quality of tumor-associated MSC. To address this question, IL-1R $^{-/-}$ mice will be inoculated with 4T1 cells, and tumor growth and MSC levels will be measured. If IL-1 β is required for MSC accumulation, we should not observe elevated levels of MSC during tumor progression. Alternatively, if IL-1 β is involved in boosting MSC levels during tumor growth rather than playing a role in initial MSC accumulation, we would expect IL-1R $^{-/-}$ inoculated mice to have equivalent levels of MSC compared to 4T1 inoculated BALB/c mice.

Additionally, the IL-1R $^{-/-}$ mice will be used to identify the origin of the intermediate cells which respond to tumor-secreted IL-1 β and induce increased levels of MSC. 4T1/IL-1 β MSC are unable to respond to IL-1 β implicating an intermediate cell which responds to IL-1 β and in response acts upon the MSC population. To determine if this effector cell is of hematopoietic or non-hematopoietic origin, we plan on creating

bone marrow chimeras using BALB/c mice reconstituted with IL-1R^{-/-} bone marrow. The reciprocal chimera using IL-1R^{-/-} mice reconstituted with BALB/c bone marrow will also be created. These chimeras will be inoculated with 4T1 cells and the levels of MSC will be measured. If hematopoietic cells are the IL-1 β responders, we should not observe an increase in MSC in the BALB/c mice with IL-1R^{-/-} bone marrow. Alternatively, if hematopoietic cells are responders, we expect to see an increase in MSC due to IL-1 β in the IL-1R^{-/-} mice with BALB/c bone marrow. Identifying the origin of the responder cell will further aid in identifying the mechanism by which IL-1 β leads to an increase in MSC and promotes immune suppression.

Key Research Accomplishments

- 4T1 cells were engineered to secrete IL-1 β and tested by ELISA.
- The 4T1/IL-1 β MSC were phenotyped and compared to the 4T1 MSC phenotype: phenotypic differences were observed suggesting different subpopulations.
- The 4T1/IL-1 β MSC were functionally analyzed and compared to 4T1 MSC: 4T1/IL-1 β MSC were more suppressive towards CD8⁺ T cells than 4T1 MSC and suppressed through a different mechanism.
- ROS production by 4T1 and 4T1/IL-1 β MSC was quantified: 4T1/IL-1 β MSC produced higher levels of ROS.
- The ability of 4T1 and 4T1/IL-1 β MSC to respond directly to tumor-secreted IL-1 β was evaluated: neither 4T1 nor 4T1/IL-1 β express the IL-1R Type I.
- Serum and tumor tissue concentrations of IL-1 β were measured: no IL-1 β was detected in serum of 4T1 or 4T1/IL-1 β inoculated mice, while IL-1 β was detected in tumor tissue of 4T1/IL-1 β inoculated mice.

Reportable Outcomes

The reported data has been presented at the following meetings:

- Keystone Symposia Meeting on Inflammation and Cancer in February 2005 in Breckenridge, CO.
- CRI Cancer Vaccines Meeting in October 2005 in New York City, NY.

The following paper was published:

- Bunt, S.K., et al. "Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression". *J Immunol.* 2006 Jan 1; **176**(1): 284-90.

A short talk entitled "Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression" is being given at the American Association of Cancer Research (AACR) Annual Meeting in April 2006 in Washington D.C.

Conclusions

The purpose of this project is to determine the mechanisms by which inflammatory factors, such as IL-1 β , promote tumor-associated immune suppression in

breast cancer. Delineating the mechanisms behind immune suppression and the factors that induce dysfunction will lead to the circumvention of suppression and will increase vaccine effectiveness and facilitate immunotherapy. Thus far, we have identified and characterized a subpopulation of tumor-associated MSC which are induced by the presence of the pro-inflammatory cytokine, IL-1 β . The next phase of this research project will focus on the mechanism by which IL-1 β enhances MSC accumulation.

References

1. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? *Lancet* 357:539.
2. Kuper, H., H. O. Adami, and D. Trichopoulos. 2000. Infections as a major preventable cause of human cancer. *J Intern Med* 248:171.
3. Shacter, E., and S. A. Weitzman. 2002. Chronic inflammation and cancer. *Oncology (Williston Park)* 16:217.
4. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. *Nature* 420:860.
5. Kusmartsev, S., and D. I. Gabrilovich. 2002. Immature myeloid cells and cancer-associated immune suppression. *Cancer Immunol Immunother* 51:293.
6. Serafini, P., C. De Santo, I. Marigo, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. *Cancer Immunol Immunother* 53:64.
7. Vakkila, J., and M. T. Lotze. 2004. Inflammation and necrosis promote tumour growth. *Nat Rev Immunol* 4:641.
8. Apte, R. N., and E. Voronov. 2002. Interleukin-1--a major pleiotropic cytokine in tumor-host interactions. *Semin Cancer Biol* 12:277.
9. Song, X., E. Voronov, T. Dvorkin, E. Fima, E. Cagnano, D. Benharroch, Y. Shendler, O. Bjorkdahl, S. Segal, C. A. Dinarello, and R. N. Apte. 2003. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. *J Immunol* 171:6448.
10. Saijo, Y., M. Tanaka, M. Miki, K. Usui, T. Suzuki, M. Maemondo, X. Hong, R. Tazawa, T. Kikuchi, K. Matsushima, and T. Nukiwa. 2002. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. *J Immunol* 169:469.
11. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. *Proc Natl Acad Sci U S A* 100:2645.
12. Vidal-Vanaclocha, F., C. Amezcua, A. Asumendi, G. Kaplanski, and C. A. Dinarello. 1994. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. *Cancer Res* 54:2667.
13. Anasagasti, M. J., E. Olaso, F. Calvo, L. Mendoza, J. J. Martin, J. Bidaurrezaga, and F. Vidal-Vanaclocha. 1997. Interleukin 1-dependent and -independent mouse melanoma metastases. *J Natl Cancer Inst* 89:645.
14. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with

- major histocompatibility complex class II and B7.1 cell-based tumor vaccines. *Cancer Res* 58:1486.
15. Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. *Cancer Res* 52:1399.
 16. Miller, F. R., B. E. Miller, and G. H. Heppner. 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. *Invasion Metastasis* 3:22.
 17. Bronte, V., P. Serafini, E. Apolloni, and P. Zanovello. 2001. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. *J Immunother* 24:431.
 18. Almand, B., J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone, and D. I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. *J Immunol* 166:678.
 19. Gabrilovich, D. I., M. P. Velders, E. M. Sotomayor, and W. M. Kast. 2001. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. *J Immunol* 166:5398.
 20. Kusmartsev, S. A., Y. Li, and S. H. Chen. 2000. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. *J Immunol* 165:779.
 21. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. *J Immunol* 174:636.

Appendices

Appendix A:

Bunt, S.K., et al. "Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression". *J Immunol*. 2006 Jan 1;176(1): 284-90.

Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression¹

Stephanie K. Bunt, Pratima Sinha, Virginia K. Clements, Jeff Leips, and Suzanne Ostrand-Rosenberg²

Epidemiological and experimental observations support the hypothesis that chronic inflammation contributes to cancer development and progression; however, the mechanisms underlying the relationship between inflammation and cancer are poorly understood. To study these mechanisms, we have transfected the mouse 4T1 mammary carcinoma with the proinflammatory cytokine IL-1 β to produce a chronic inflammatory microenvironment at the tumor site. Mice with 4T1/IL-1 β tumors have a decreased survival time and elevated levels of immature splenic Gr1⁺CD11b⁺ myeloid-derived cells. These myeloid suppressor cells (MSC) are present in many patients with cancer and inhibit the activation of CD4⁺ and CD8⁺ T lymphocytes. 4T1/IL-1 β -induced MSC do not express the IL-1R, suggesting that the cytokine does not directly activate MSC. Neither T or B cells nor NKT cells are involved in the IL-1 β -induced increase of MSC because RAG2^{-/-} mice and nude mice with 4T1/IL-1 β tumors also have elevated MSC levels. MSC levels remain elevated in mice inoculated with 4T1/IL-1 β even after the primary tumor is surgically removed, indicating that the IL-1 β effect is long lived. Collectively, these findings suggest that inflammation promotes malignancy via proinflammatory cytokines, such as IL-1 β , which enhance immune suppression through the induction of MSC, thereby counteracting immune surveillance and allowing the outgrowth and proliferation of malignant cells. *The Journal of Immunology*, 2006, 176: 284–290.

The concept that chronic inflammation promotes tumor progression was originally proposed by Virchow in the late 1800s (1). Epidemiological studies offer strong support for this concept. For example, the risk of some organ-specific cancers, particularly colorectal cancers, is significantly higher in individuals with chronic inflammation of the target organ (1–4). Experimental findings also support the observation that inflammation facilitates malignant growth. Inflammatory components have been shown 1) to induce DNA damage, which contributes to genetic instability and transformed cell proliferation (1); 2) to promote angiogenesis and thereby enhance tumor growth and invasiveness (4); and 3) to impair myelopoiesis and hemopoiesis, which cause immune dysfunction and inhibit immune surveillance (5, 6). Although it is generally accepted that inflammation enhances tumor progression (1, 4, 7), the mechanisms by which inflammation mediates its effects are not well understood.

To study these mechanisms, we have developed an experimental system in which tumors constitutively express the proinflammatory cytokine, IL-1 β , resulting in an inflammatory microenvironment at the tumor site. We have used IL-1 β because it is a key cytokine in mediating an inflammatory response (8) and has been previously shown to promote primary tumor growth (8–11) and to enhance metastatic disease (11–13). The spontaneously metastatic

BALB/c-derived 4T1 mammary carcinoma (14–16) was used because breast cancer is one of the cancers for which inflammation is associated with poor prognosis (6) and because we want to study the effects of inflammation on the progression of both primary and metastatic tumor.

In addition to confirming the concept that a proinflammatory microenvironment enhances tumor progression, our results suggest a novel mechanism by which inflammation facilitates tumor growth. We find that IL-1 β -producing tumor cells are potent inducers of a population of immature Gr1⁺CD11b⁺ myeloid-derived cells called myeloid suppressor cells (MSC)³. Elevated levels of MSC are frequently found in many cancer patients and cause a global and profound immune suppression (5, 6, 17–20). The IL-1 β -induced MSC described in this study are effective suppressors of CD4⁺ and CD8⁺ T lymphocytes. The finding that IL-1 β up-regulates MSC accumulation in tumor-bearing mice has led us to propose the following causal relationship linking chronic inflammation with tumor progression: as tumor cells proliferate they induce an inflammatory microenvironment consisting of IL-1 β and other proinflammatory mediators. The persistence of these mediators causes the accumulation and retention of MSC. The MSC, in turn, initiate and maintain an immune suppressive state that block immune surveillance, thereby facilitating the survival and proliferation of transformed cells.

Materials and Methods

Mice

BALB/c and D011.10 transgenic mice (21) (both from The Jackson Laboratory), RAG2^{-/-} mice (Taconic Farms), and clone 4 transgenic mice (22, 23) were bred in the University of Maryland Baltimore County (UMBC) animal facility (Baltimore, MD). BALB/c nude mice were obtained

Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250

Received for publication July 20, 2005. Accepted for publication October 18, 2005.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by Grants CA52527 and CA84232 from the National Institutes of Health and Grant DAMD-17-01-1-0312 from the Department of Defense. S.K.B. is supported by a predoctoral fellowship from the Department of Defense Breast Cancer Research Program W81XWH-05-1-0276.

² Address correspondence and reprint requests to Dr. Suzanne Ostrand-Rosenberg, Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250. E-mail address: srosenbe@umbc.edu

³ Abbreviations used in this paper: MSC, myeloid suppressor cell; ROS, reactive oxygen species; hIL-1, human IL-1; D-NMMA, N^G-monomethyl-D-arginine; L-NMMA, N^G-monomethyl-L-arginine; Nor-NOHA, N^W-hydroxy-nor-L-arginine; ssIL-1 β , signal sequence IL-1 β ; HA, influenza hemagglutinin.

from the National Cancer Institute (Frederick, MD). All animal procedures have been approved by the UMBC Institutional Animal Care and Use Committee.

Cell lines

The 4T1 mammary carcinoma cell line was maintained as described (24). The LBRM TG6 mouse T cell lymphoma cell line (American Type Culture Collection) was cultured in IMDM (BioSource International) supplemented with 10% fetal clone 1 (FBP; HyClone Laboratories), 1% glutamax (Invitrogen Life Technologies), 1% gentamicin sulfate (BioSource International), 1% antibiotic-antimycotic solution (BioSource International), and 0.02 mM 2-ME (J. T. Baker Chemical). The 293T cells were maintained as described (25). 4T1 transductants were grown in the same medium as the parental cells supplemented with 400 or 600 μ g/ml G418 (Sigma-Aldrich) for 4T1/RV and 4T1/IL-1 β cells, respectively. 4T1/IL-1 β cells cultured in vivo or grown as solid tumors in mice secreted similar amounts of IL-1 β as measured by ELISA.

Reagents and Abs

OVA_{323–339} and HA_{518–526} peptides were synthesized in the Biopolymer Core Facility at the University of Maryland Medical School (Baltimore, MD). mAbs Gr1-PE, CD11b-FITC, CD3-FITC, CD4-PE, CD8-PE, B220-PE, CD11c-PE, I-A/I-E-FITC, D α -FITC, CD86-PE, CD80-FITC, CD40-PE, CD44-FITC, CD14-FITC, CD23-FITC, CD31-FITC, CD34-FITC, CD16/CD32-FITC, rat IgG2 α -PE isotype control, and rat IgG2 α -FITC isotype control were from BD Pharmingen. F4/80-FITC was from Caltag Laboratories; PDL2-PE from eBioscience; CD83-FITC from BioCarta; and DEC205-FITC from Cedarlane Laboratories. Rat anti-mouse Gr-1 (clone RB6-8C5) and goat anti-rat IgG microbeads for MSC sorting were from BD Pharmingen and Miltenyi Biotec, respectively. DCFDA (dichlorodihydrofluorescein diacetate) for ROS detection was from Molecular Probes.

Plasmids, retroviral vectors, and transductions

The pLXSN/ssIL-1 β plasmid containing the signal sequence of the IL-1 α fused to the mature hIL-1 β gene (26) was used to transduce 4T1 cells to create the 4T1/IL-1 β cell line. The 4T1/RV cell line, a retroviral vector control, was created by transduction of 4T1 parental cells with the pLNCX2/AvrII plasmid (Clontech Laboratories). 4T1/RV cells were identical with 4T1 parental cells in their phenotype and in vivo growth; hence, the results for these lines are pooled and labeled as 4T1. Retroviral production and transduction were as previously described (25). Briefly, 293T cells were plated in six-well plates at 1×10^6 cells/well and transfected by the CaCl₂ method with the group-specific Ag, polymerase, and envelope genes, and pLXSN/ssIL-1 β plasmid. After 48 h, viral supernatants were collected. To create 4T1/IL-1 β cells, 4T1 cells were plated in six-well plates at 1×10^5 cells/well 15–18 h before the addition of polybrene (4 μ g/ml) and viral ssIL-1 β supernatants (500 μ l/well). Cells were incubated at 37°C for 5–6 h, washed with sterile PBS, and cultured an additional 48 h before G418 selection was added.

Tumor inoculations, surgery, and metastasis (clonogenic) assay

Female 6- to 10-wk-old BALB/c mice were inoculated on day 0 in the mammary fat pad with 7×10^3 tumor cells in 50 μ l of PBS. Primary tumors were measured as described (14). Survival time indicates the day after tumor inoculation when mice are moribund and are sacrificed. For metastasis assays, lungs were harvested at the indicated times and metastatic disease was quantified using the clonogenic assay by plating cells in 6-thioguanine supplemented medium (14).

Splenic MSC

Gr1⁺CD11b⁺ MSC were isolated from the spleen of tumor-bearing mice using MACS (Miltenyi Scientific) as described (27).

T cell proliferation assays

The CD4⁺ and CD8⁺ T cell proliferation assays were performed as described (27). Briefly, DO11.10 or clone 4 splenocytes were cocultured with OVA or influenza hemagglutinin (HA) peptide, respectively, and irradiated MACS purified splenic MSC from BALB/c mice inoculated with 4T1 or 4T1/IL-1 β cells. Cultures were pulsed with [³H]thymidine on day 3 and cells were harvested 24 h later. For the arginase and NO assays, the NO inhibitor N^G-monomethyl-L-arginine (L-NMMA), the enantiomer N^G-monomethyl-D-arginine (D-NMMA), or the arginase inhibitor N^W-hydroxy-nor-L-arginine (nor-NOHA) (Calbiochem) was added. Data are expressed as the average cpm of triplicate wells.

Arginase assay

Arginase was quantified by measuring the production of urea as described (27).

Flow cytometry

Cells were labeled for direct immunofluorescence as described (14) and analyzed using an Epics XL flow cytometer using the Expo32 ADC software (Beckman Coulter).

IL-1 β Fluorokine assay

The IL-1R Fluorokine assay was performed according to the manufacturer's instructions (R&D Systems). Briefly, 1×10^5 purified MSC from tumor-bearing mice were incubated with either 10 μ l of rIL-1 β -biotin or negative control biotinylated soybean protein for 1 h at 4°C and then incubated with 10 μ l of avidin-FITC for 30 min at 4°C in the dark. Cells were washed twice with 1X RFD1 buffer and analyzed by flow cytometry for IL-1R expression.

Reactive oxygen species (ROS)

ROS production was measured by staining with DCFDA as described (27). To block ROS production, MSC were incubated with nor-NOHA at 37°C for 10 min before DCFDA addition. Cells were washed with sterile PBS and assayed by flow cytometry (27).

IL-1 β ELISA

Supernatants from 5×10^5 cells cultured in 3 ml of media for 24 h were frozen at –80°C until assayed using a hIL-1 β ELISA kit according to the manufacturer's directions (Endogen). Plates were read at 420 nm on a Bio-Tek 311 microplate reader and quantified using a standard curve. Data are the mean $\pm$ SD of triplicate wells.

Statistical analyses

Student's two-tailed *t* test for unequal variance was performed for all figures using Microsoft Excel 2003. Differences in tumor diameter in the inoculated mice were tested using a repeated measures profile ANOVA (28, 29) using the procedure in SAS v.9.1 (SAS Institute) (see Fig. 4A).

Results

Transduced 4T1 cells secrete mature functional IL-1 β

To examine the role of inflammation and IL-1 β on the development and progression of breast cancer, 4T1 mammary carcinoma cells were transduced with a construct containing the mature form of hIL-1 β fused to the signal sequence from the IL-1 α (ssIL-1 β construct; 4T1/IL-1 β cells), allowing active hIL-1 β to be secreted extracellularly (26). 4T1/IL-1 β cells secreted 1000 pg/ml/5 $\times 10^5$ /24 h as quantified by ELISA. As a control for transduction with a retroviral vector, 4T1 cells were transduced with an empty vector (4T1/RV). To evaluate whether the transduction or the secretion of IL-1 β altered growth rate, 4T1 and 4T1/IL-1 β cells were plated at equivalent densities and counted every 24 h for 3 days. Both lines had the same growth kinetics, indicating that IL-1 β transduction did not affect the in vitro growth rate. To further characterize the 4T1/IL-1 β cells, MHC class I and class II surface expression was analyzed by flow cytometry. Transduction of 4T1 cells with ssIL-1 β did not alter the amount of H-2D^d, and neither 4T1 nor 4T1/IL-1 β cells express MHC class II. MHC class I and class II phenotype and in vivo growth of 4T1 and 4T1/RV cells were identical, so results of these controls were pooled and are labeled as 4T1 in these experiments.

IL-1 β enhances primary tumor growth and decreases survival time

To examine the role of IL-1 β on primary tumor onset and growth, 4T1 and 4T1/IL-1 β cells were injected into BALB/c mice on day 0. For both groups, primary tumors were measured every 3–5 days and were palpable by day 10. 4T1/IL-1 β primary tumors grew significantly faster than parental 4T1 primary tumors ($p < 0.01$). To determine whether IL-1 β affects survival, 4T1- and 4T1/IL-1 β -injected mice were followed until they were moribund. 4T1/

IL-1 β -injected mice had significantly reduced survival time ($p < 0.01$; 26–44 days with a mean of 37 days; $n = 13$), compared with 4T1-injected mice (33–60 days with a mean of 46 days; $n = 15$). These data indicate that IL-1 β increases the primary tumor growth rate and suggest that the difference in survival may be due to enhanced tumor progression.

IL-1 β leads to an earlier and faster accumulation of MSC

Because MSC frequently accumulate in tumor-bearing individuals and can reduce survival time, we examined MSC levels in mice with 4T1/IL-1 β vs 4T1 tumors. BALB/c mice were inoculated with 4T1 or 4T1/IL-1 β cells and the percentage of splenic MSC was measured as a function of time after tumor inoculation. Mice with 4T1/IL-1 β tumors have higher levels of MSC than mice with 4T1 tumors (Fig. 1A). Because MSC accumulation is known to increase with increasing tumor burden, mice with 4T1/IL-1 β tumors may have more MSC because their primary tumors are larger. To address this question, the percentage of splenic MSC was plotted relative to tumor diameter. As seen in Fig. 1B, MSC levels are consistently higher in 4T1/IL-1 β vs 4T1 mice regardless of the size of their primary tumors. Additionally, increased levels of MSC in other organs, such as the lungs, were also elevated in 4T1/IL-1 β tumor-bearing mice, compared with 4T1 tumor-bearing mice (data not shown), suggesting that IL-1 β secretion by the primary tumor systemically enhances MSC accumulation. These data indicate that IL-1 β induces the accumulation of elevated levels of MSC.

Mice with IL-1 β tumors do not have more lung metastases

To determine whether IL-1 β affects the progression of lung metastases, BALB/c mice were injected with 4T1 or 4T1/IL-1 β cells and lungs were harvested 5 wk later or when the mice were moribund. The number of lung metastases was quantified using the clonogenic assay (14). Both 4T1- and 4T1/IL-1 β -injected mice developed lung metastases (Fig. 2). There is no difference in the number of lung metastases between 4T1- and 4T1/IL-1 β -injected




FIGURE 1. IL-1 β increases the accumulation of splenic MSC. BALB/c mice were inoculated with 7000 4T1 or 4T1/IL-1 β tumor cells in the abdominal mammary gland on day 0. Spleens were harvested at the indicated time points (A) or tumor diameters (B), and Gr1⁺CD11b⁺ MSC were quantified by flow cytometry. Values are the average $\pm$ SD of 5–18 and 5–19 mice per group for A and B, respectively. Data are pooled from five experiments. 4T1 and 4T1/IL-1 β groups are statistically significantly different ($p < 0.05$) from each other for all time periods and tumor diameters.




FIGURE 2. IL-1 β does not alter the number of lung metastases. BALB/c mice were inoculated with 4T1 or 4T1/IL-1 β tumor cells as in Fig. 1 and their lungs harvested at the indicated times. Metastatic cells were quantified using the clonogenic assay. Individual mice (●) are represented. Horizontal bars indicate the mean number of metastases. Data are pooled from four independent experiments.

mice at week 5; however, when the mice become moribund, 4T1/IL-1 β -injected mice have fewer lung metastases ($p < 0.05$), compared with 4T1-injected mice. These results indicate that IL-1 β does not increase the number of metastatic cells in the lungs and suggest that IL-1 β is not reducing survival time by increasing metastatic disease.

4T1 and 4T1/IL-1 β cells do not express the IL-1R type I

IL-1 β may be mediating its effect by acting directly on 4T1 tumor cells or on host cells. To determine whether 4T1/IL-1 β cells had the potential to respond to IL-1 β , 4T1 and 4T1/IL-1 β cells were labeled with fluorescent IL-1 β protein and analyzed by flow cytometry. LBRM TG6 cells, which express the IL-1R type I, were used as positive control cells. Neither 4T1 nor 4T1/IL-1 β cells express detectable IL-1R type I indicating that these cells cannot respond to IL-1 β (Fig. 3). These results implicate host cells as the responders to the tumor-secreted IL-1 β .

IL-1 β -induced tumor growth is not dependent on host T cells, B cells, or NKT cells

Immunodeficient and knockout mice were used to determine whether host immune cells are required for the IL-1 β effect. Wild-type BALB/c mice and RAG2^{-/-} BALB/c mice, which are deficient for T cells, B cells, and NKT cells, were inoculated with 4T1 or 4T1/IL-1 β cells and primary tumor growth was measured every 3–5 days (Fig. 4A). 4T1/IL-1 β primary tumors grew significantly more rapidly in both BALB/c and RAG2^{-/-} mice ($p < 0.01$) and mice with 4T1/IL-1 β tumors became moribund sooner than mice with 4T1 tumors. Therefore the increased tumorigenicity of 4T1/IL-1 β tumor cells is not dependent on host lymphoid cells.




FIGURE 3. 4T1 and 4T1/IL-1 β tumor cells do not express the IL-1R type I. 4T1 and 4T1/IL-1 β tumor cells were stained with avidin-FITC and either biotinylated rIL-1 β protein (solid line histogram) or biotinylated soybean protein (dashed histogram) and analyzed by flow cytometry. Soybean protein expression levels were identical on 4T1 and 4T1/IL-1 β tumor cells and are shown as a single peak. Data are from one of three independent experiments.




FIGURE 4. T cells, B cells, and NKT cells are not required for the IL-1 β -induced accumulation of MSC. BALB/c and RAG2^{-/-} mice were inoculated with 4T1 or 4T1/IL-1 β tumor cells and monitored for primary tumor growth and survival. **A**, Primary tumor diameter plotted as a function of time after tumor inoculation. Each curve represents an average of 3–8 mice. Growth of primary 4T1/IL-1 β tumors is more rapid than growth of primary 4T1 tumors in both strains ($p < 0.01$). **B**, Lung metastases were quantified from the mice in **A** using the clonogenic assay. Individual mice are represented (●) and horizontal bars indicate the mean number of lung metastases. **C**, BALB/c, nude, and RAG2^{-/-} mice bearing 4T1 or 4T1/IL-1 β tumors were euthanized at week 5 and the percentage of splenic Gr1⁺CD11b⁺ MSC was quantified by flow cytometry. All columns are statistically significantly different ($p < 0.01$) from other columns in the same strain and in other strains (including RAG2^{-/-} with 4T1 vs RAG2^{-/-} with 4T1/IL-1 β) except BALB/c with 4T1 vs nude with 4T1 and BALB/c with 4T1/IL-1 β vs nude with 4T1/IL-1 β .

To determine whether lymphoid cells influence metastatic disease, wild-type BALB/c and RAG2^{-/-} mice were inoculated with 4T1 and 4T1/IL-1 β cells on day 0 and their lungs were harvested between days 25 and 35. Metastases were quantified using the clonogenic assay. IL-1 β expression did not affect the average number of lung metastases in BALB/c mice; however, IL-1 β induced a significant increase ($p = 0.05$) in the number of lung metastases in RAG2^{-/-} mice (Fig. 4B). RAG2^{-/-} mice with 4T1/IL-1 β tumors have a statistically higher number of metastases, compared with BALB/c mice with 4T1/IL-1 β tumors. Therefore, the presence of B cell, T cell, and NKT cells naturally limits the increase in lung metastases by IL-1 β .

Enhanced splenic MSC accumulation by IL-1 β does not require T cells, B cells, or NKT cells

To determine whether host lymphoid cells are required for the IL-1 β -induced increase in MSC, BALB/c, T cell-deficient nude, and RAG2^{-/-} mice were inoculated with 4T1 or 4T1/IL-1 β cells and their splenocytes harvested on days 25–35 and assayed by flow cytometry for Gr1⁺CD11b⁺ cells. All strains with 4T1/IL-1 β tumors had significantly more splenic MSC than mice with 4T1 tumors (including RAG2^{-/-} with 4T1 vs RAG2^{-/-} with 4T1/IL-1 β ; $p < 0.01$) (Fig. 4C), confirming the findings of Fig. 1A and demonstrating that the ability of IL-1 β to elevate MSC does not require lymphoid cells. Interestingly, BALB/c and nude mice with 4T1/IL-1 β tumors had similar MSC levels, whereas RAG2^{-/-} mice with 4T1/IL-1 β tumors had significantly higher numbers of MSC. Therefore, although lymphoid cells are not required for the IL-1 β -induced effect, deletion of $\gamma\delta$ T cells and/or B cells appears to facilitate an even larger accumulation of MSC.

IL-1 β -induced MSC are phenotypically distinct from 4T1 MSC

IL-1 β may be augmenting an existing population of MSC, or it may be inducing a novel population. To distinguish between these two possibilities, BALB/c mice were injected on day 0 with 4T1 or 4T1/IL-1 β cells, and splenic MSC were sorted by MACS for Gr1⁺ cells on day 35. Sorted cells were >90% Gr1⁺CD11b⁺ as measured by flow cytometry (Fig. 5A). Fig. 5B shows the phenotype of the purified Gr1⁺CD11b⁺ cells for various cell surface markers that have been used to characterize MSC. 4T1/IL-1 β MSC expressed higher levels of CD8, CD80, CD83, and CD14 and lower levels of CD44 and B220 relative to 4T1 MSC. To evaluate whether these differences were a result of direct action of IL-1 β the MSC were stained for the IL-1R type I. Both 4T1- and 4T1/IL-1 β -induced MSC were negative for the IL-1R type I indicating that MSC cannot respond directly to IL-1 β . Therefore, 4T1 and 4T1/IL-1 β MSC share some common markers; however, they also have phenotypic differences.

IL-1 β -induced MSC suppress CD4⁺ and CD8⁺ T cells

Previous data demonstrate that 4T1-induced MSC suppress both CD4⁺ and CD8⁺ T cells via an arginase-dependent mechanism (27). Because IL-1 β -induced MSC phenotypically differ from 4T1-induced MSC, it is possible that the 4T1/IL-1 β MSC are also functionally distinct. To determine whether 4T1/IL-1 β MSC have different functional activity from 4T1 MSC, BALB/c mice were injected with 4T1 and 4T1/IL-1 β cells on day 0, and splenic MSC were harvested and purified by MACS on day 35, and tested for their ability to inhibit T cell proliferation. To test for suppressive activity against CD4⁺ T cells, I-A^d-restricted OVA_{323–339} peptide-specific DO11.10 transgenic splenocytes were stimulated with OVA_{323–339} peptide in the presence or absence of purified MSC from 4T1- or 4T1/IL-1 β -inoculated mice (Fig. 6A). Both 4T1 and 4T1/IL-1 β MSC suppressed DO11.10 proliferation by >95% as measured by [³H]thymidine uptake. To identify the molecule mediating this suppression, L-NMMA or nor-NOHA, inhibitors of NO and arginase, respectively, were added to the DO11.10 cultures. Nor-NOHA treatment partially reversed suppression by both 4T1 and 4T1/IL-1 β MSC, whereas L-NMMA treatment had no effect. Arginase levels in 4T1- and 4T1/IL-1 β -induced MSC were equivalent as measured enzymatically (data not shown). Therefore, 4T1/IL-1 β - and 4T1-induced MSC are equally suppressive for CD4⁺ T cells, and they both at least partially mediate their effect via arginase.

To determine whether 4T1 IL-1 β MSC also block CD8⁺ T cell activation, HA_{518–526} peptide-specific, K^d-restricted clone 4 transgenic splenocytes were stimulated with HA_{518–526} peptide and




FIGURE 5. MSC from mice with 4T1/IL-1 β tumors and MSC from mice with 4T1 tumors have phenotypic differences. BALB/c mice were inoculated with 4T1 or 4T1/IL-1 β tumor cells, and spleens were harvested when tumor diameters reached 8–10 mm. **A**, MACS-purified MSC were analyzed by flow cytometry for Gr1 and CD11b expression. **B**, MACS-purified MSC were phenotyped with mAbs to the indicated markers. Dotted histograms are controls (fluorescently labeled soybean protein for IL-1R sample or anti-rat isotype-FITC and anti-rat isotype-PE Abs for all other samples; 4T1 and 4T1/IL-1 β MSC had the same fluorescent staining for controls, hence only one peak is shown). Black solid line histograms and gray-filled histograms are MSC from 4T1- and 4T1/IL-1 β -inoculated mice, respectively. Data are from one of three independent experiments.

cocultured in the presence or absence of purified 4T1 or 4T1/IL-1 β MSC. Although both 4T1 and 4T1/IL-1 β MSC suppress CD8 $^{+}$ T cell activation, 4T1/IL-1 β MSC are more suppressive on a per cell




FIGURE 6. MSC from mice with 4T1/IL-1 β tumors express increased levels of ROS and suppress CD4 $^{+}$ and CD8 $^{+}$ T cells. CD4 $^{+}$ DO11.10 (**A**) or CD8 $^{+}$ clone 4 (**B**) transgenic splenocytes were stimulated with OVA_{323–339} or HA_{518–526} peptide, respectively, and cocultured in the presence or absence of MACS-purified MSC from mice with 4T1 or 4T1/IL-1 β tumors. Inhibitors of arginase (nor-NOHA), NO (L-NMMA), or the inactive enantiomer (D-NMMA) were added to some wells. T cell proliferation was measured as cpm of [3 H]thymidine. Data are from one of four independent experiments. **A** and **B**, Nor-NOHA-treated groups are statistically significantly different ($p < 0.05$) from their untreated counterparts. **B**, Nor-NOHA-treated 4T1 MSC are also statistically significantly different ($p < 0.05$) from nor-NOHA-treated 4T1/IL-1 β MSC. **C**, MACS-purified MSC from mice with 4T1 or 4T1/IL-1 β tumors were incubated with DCFDA in the presence or absence of the arginase inhibitor nor-NOHA and ROS production was measured by flow cytometry. Data are from one of three independent experiments.

basis than 4T1 MSC (Fig. 6B; $p < 0.01$). However, in contrast to results of Fig. 6A, addition of the arginase inhibitor nor-NOHA does not reverse the suppression by 4T1/IL-1 β MSC. Likewise, no reversal of suppression was observed when the NO inhibitor L-NMMA or its inactive enantiomer D-NMMA was added. Therefore, 4T1/IL-1 β MSC are more effective suppressors of CD8 $^{+}$ T cells than are 4T1 MSC, and they suppress by an arginase-independent mechanism.

IL-1 β -induced MSC express higher levels of ROS

To determine whether 4T1 and 4T1/IL-1 β MSC differ in other potential effector mechanisms, ROS expression was analyzed in the two populations. MACS purified MSC from 4T1- and 4T1/IL-1 β -injected BALB/c mice were stained with DCFDA and analyzed by flow cytometry. Both 4T1 and 4T1/IL-1 β MSC have high levels of ROS; however, 4T1/IL-1 β MSC contain more ROS (Fig. 6C). The addition of nor-NOHA differentially decreases but does not eliminate ROS levels. Therefore, 4T1/IL-1 β MSC express more ROS on a per cell basis than 4T1 MSC, and a significant amount of this ROS production is affected by arginase production.

4T1/IL-1 β MSC remain elevated even when primary tumor is removed

Surgical excision of primary 4T1 tumor from BALB/c mice leads to a partial regression of splenic MSC (27). To determine whether IL-1 β affects this regression, BALB/c mice were inoculated with 4T1 or 4T1/IL-1 β cells on day 0, and primary tumors were either left in place (nonsurgery group) or removed (surgery group) on day 25. Both groups were sacrificed on day 35, and the percentages of Gr1⁺CD11b⁺ splenic MSC were compared. As observed previously (27), surgical excision of the 4T1 tumor caused a significant decrease in MSC (Fig. 7A; $p < 0.01$). In contrast, there was no significant decrease in MSC in mice with resected 4T1/IL-1 β tumors. These results imply that secretion of IL-1 β by the primary tumor either irreversibly enhances MSC accumulation or the presence of residual IL-1 β prevents the regression of MSC.

To evaluate the effect of IL-1 β on metastatic disease after primary tumor removal, the number of metastatic cells in the lungs of the mice in Fig. 7A was quantified using the clonogenic assay. No

differences in lung metastases were seen (Fig. 7B), in agreement with the results of Fig. 2 that IL-1 β does not impact metastatic disease.

Discussion

Although the concept that chronic inflammation in the tumor microenvironment leads to increased malignant growth and tumor progression is broadly accepted, the mechanisms behind this interaction have remained elusive. The results presented in this study suggest that the induction of MSC by proinflammatory cytokines directly contributes to tumor progression by inhibiting tumor immunity. Cell-mediated immunity is known to protect against tumor onset and progression (30, 31), and MSC are known to block this process. Therefore, it is likely that the MSC induced during an inflammatory response facilitate tumor growth by inhibiting the activation and/or function of tumor-specific lymphocytes. This novel mechanism is consistent with the findings that MSC are found in many cancer patients, particularly patients who have head and neck cancers, lung carcinomas, or breast cancers (5, 6, 17–19), and that chronic inflammation in some of these malignancies, such as oral, esophageal, and lung cancers, may predispose to or enhance malignant growth (4). Chronic inflammation associated with infectious agents, such as schistosomiasis and *Helicobacter pylori*, is also thought to predispose to malignancy (1, 3, 32, 33), and some of these agents are associated with MSC accumulation (6). Collectively, these published observations plus our reported results support the hypothesis that chronic inflammation facilitates tumor growth by inducing MSC that down-regulate immune surveillance, thereby providing an environment favorable for tumor progression.

Previous studies have examined the effects of IL-1 β on tumorigenicity by transfecting/transducing tumor cells with this cytokine. Most investigators find that IL-1 β enhances tumor progression (9, 10), although a minority of reports indicates that it inhibits tumor growth (34, 35). These contradictory results are likely due to the different tumor systems studied and/or to the different amounts of IL-1 β secreted by the various transfectants (as suggested by Ref. 8). IL-1 β acts on many cell types, inducing a variety of effects including increased production of PGE₂, vascular endothelial growth factor, IL-6, and circulating levels of GM-CSF (36). Because all of these molecules have been suggested as inducers of MSC (5, 6), one or more of them may be the vehicle for IL-1 β -induced immune suppression.

IL-1 β was selected for these experiments because it is a pleiotropic cytokine that produces its effect through a wide array of mechanisms, cell types, and molecules (36). Because neither MSC nor 4T1 tumor cells contain a receptor for IL-1 β , it is improbable that IL-1 β is the direct inducer of MSC. More likely, IL-1 β regulates MSC levels by activating a signal transduction pathway that stimulates cells, which then secrete factors that directly induce MSC accumulation. Many cell types express the IL-1R type I allowing them to respond to the cytokine (8, 36), and hence are potential candidates. Alternatively, IL-1 β may regulate MSC accumulation by down-regulating cells and/or factors that normally minimize MSC expansion. This possibility is supported by the findings that tumor-bearing RAG2^{-/-} mice have higher levels of MSC than wild-type BALB/c or nude mice, implying that $\gamma\delta$ T cells and/or B cells normally limit the tumor-associated expansion of splenic MSC.

Although MSC are present in many tumor-bearing patients and experimental animals, there is significant phenotypic variation between MSC from different individuals (19, 27, 37, 38), suggesting there are distinct subpopulations of MSC (27). The observation that 4T1/IL-1 β -induced MSC differentially express some cell surface markers relative to 4T1-induced MSC further supports the




FIGURE 7. MSC do not regress after surgical resection of primary 4T1/IL-1 β tumors. BALB/c mice were inoculated with 4T1 or 4T1/IL-1 β tumor cells as in Fig. 1 and the primary tumors were either left intact (nonsurgery groups) or surgically excised on day 25 (surgery groups). Lungs and spleens were harvested on day 35. **A**, The percentage of Gr1⁺CD11b⁺ splenic MSC was quantified by flow cytometry. Values are the average of 7–19 animals per group and are pooled from two independent experiments. **B**, Lung metastases were quantified using the clonogenic assay. Individual mice (●) are represented, and horizontal bars indicate the mean number of metastases.

concept of MSC heterogeneity. However, this finding also raises the question of whether overexpression of IL-1 β induces a distinct MSC subpopulation or whether it expands and modifies the MSC induced by wild-type 4T1 tumor. Compared with 4T1 MSC, 4T1/IL-1 β MSC expressed higher levels of CD8, CD80, and CD83, a marker expressed by mature dendritic cells and activated lymphocytes. Additionally, expression of the LPS receptor CD14, usually expressed by macrophages and/or monocytes, was increased on 4T1/IL-1 β MSC. 4T1/IL-1 β MSC also expressed lower levels of the B cell marker, B220, and the cell adhesion marker, CD44. Although, the 4T1/IL-1 β MSC phenotype suggests a partially activated cell, these surface markers do not classify the MSC into any known cellular category. It is interesting that CD14 is elevated only on 4T1/IL-1 β MSC, suggesting that IL-1 β production stimulates CD14 expression. CD14 has been shown to couple with TLR4, which can also complex with IL-1R, and leads to the activation of NF- κ B, cyclooxygenase-2, and PGE₂ (39, 40). This pathway may be one of the mechanisms responsible for IL-1 β -induced MSC accumulation and survival and deserves further study.

Although these phenotypic differences exist, it is unclear whether they are biologically significant, because 4T1- and 4T1/IL-1 β -induced MSC are both highly immunosuppressive for CD4⁺ and CD8⁺ T cells. Experiments with wild-type 4T1 tumor have shown that surgical removal of primary tumor reduces MSC levels (27) and restores host immunocompetence (41). In contrast, mice with resected 4T1/IL-1 β tumors retain very high levels of MSC, suggesting that inflammation-induced MSC are likely to be a significant obstacle to effective immunotherapy.

Acknowledgments

We thank Drs. Ron Apte and Ephraim Fuchs for providing the ssIL-1 β construct and the clone 4 mice, respectively; Brian Dolan for creating the 4T1/RV cell line; and Sandy Mason for excellent care of our mice.

Disclosures

The authors have no financial conflict of interest.

References

- Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? *Lancet* 357: 539–545.
- Kuper, H., H. O. Adami, and D. Trichopoulos. 2000. Infections as a major preventable cause of human cancer. *J. Intern. Med.* 248: 171–183.
- Shacter, E., and S. A. Weitzman. 2002. Chronic inflammation and cancer. *Oncology* 16: 217–226.
- Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. *Nature* 420: 860–867.
- Kusmartsev, S., and D. I. Gabrilovich. 2002. Immature myeloid cells and cancer-associated immune suppression. *Cancer Immunol. Immunother.* 51: 293–298.
- Serafini, P., C. De Santo, I. Marigo, S. Cingolani, L. Dolcetti, G. Gallina, P. Zanoello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. *Cancer Immunol. Immunother.* 53: 64–72.
- Vakkila, J., and M. T. Lotze. 2004. Inflammation and necrosis promote tumour growth. *Nat. Rev. Immunol.* 4: 641–648.
- Apte, R. N., and E. Voronov. 2002. Interleukin-1: a major pleiotropic cytokine in tumor-host interactions. *Semin. Cancer Biol.* 12: 277–290.
- Song, X., E. Voronov, T. Dvorkin, E. Fima, E. Cagnano, D. Benharroch, Y. Shendler, O. Björkdahl, S. Segal, C. A. Dinarello, and R. N. Apte. 2003. Differential effects of IL-1 α and IL-1 β on tumorigenicity patterns and invasiveness. *J. Immunol.* 171: 6448–6456.
- Saijo, Y., M. Tanaka, M. Miki, K. Usui, T. Suzuki, M. Maemondo, X. Hong, R. Tazawa, T. Kikuchi, K. Matsushima, and T. Nukiwa. 2002. Proinflammatory cytokine IL-1 β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. *J. Immunol.* 169: 469–475.
- Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. *Proc. Natl. Acad. Sci. USA* 100: 2645–2650.
- Vidal-Vanaclocha, F., C. Amezcua, A. Asumendi, G. Kaplanski, and C. A. Dinarello. 1994. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. *Cancer Res.* 54: 2667–2672.
- Anasagasti, M. J., E. Olaso, F. Calvo, L. Mendoza, J. J. Martin, J. Bidaurreaga, and F. Vidal-Vanaclocha. 1997. Interleukin-1-dependent and -independent mouse melanoma metastases. *J. Natl. Cancer Inst.* 89: 645–651.
- Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. *Cancer Res.* 58: 1486–1493.
- Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. *Cancer Res.* 52: 1399–1405.
- Miller, F. R., B. E. Miller, and G. H. Heppner. 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. *Invasion Metastasis* 3: 22–31.
- Bronte, V., P. Serafini, E. Apolloni, and P. Zanoello. 2001. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. *J. Immunother.* 24: 431–446.
- Almand, B., J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone, and D. I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. *J. Immunol.* 166: 678–689.
- Gabrilovich, D. I., M. P. Velders, E. M. Sotomayor, and W. M. Kast. 2001. Mechanism of immune dysfunction in cancer mediated by immature Gr-1⁺ myeloid cells. *J. Immunol.* 166: 5398–5406.
- Kusmartsev, S. A., Y. Li, and S. H. Chen. 2000. Gr-1⁺ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. *J. Immunol.* 165: 779–785.
- Murphy, K. M., A. B. Heimberger, and D. Y. Loh. 1990. Induction by antigen of intrathymic apoptosis of CD4⁺CD8⁺TCR^{lo} thymocytes in vivo. *Science* 250: 1720–1723.
- Morgan, D. J., R. Liblau, B. Scott, S. Fleck, H. O. McDevitt, N. Sarvetnick, D. Lo, and L. A. Sherman. 1996. CD8⁺ T cell-mediated spontaneous diabetes in neonatal mice. *J. Immunol.* 157: 978–983.
- Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. *J. Immunol.* 160: 643–651.
- Ostrand-Rosenberg, S., M. J. Grusby, and V. K. Clements. 2000. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. *J. Immunol.* 165: 6015–6019.
- Dissanayake, S. K., J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg. 2004. Activation of tumor-specific CD4⁺ T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. *Cancer Res.* 64: 1867–1874.
- Wingren, A. G., O. Björkdahl, T. Labuda, L. Björk, U. Andersson, U. Gullberg, G. Hedlund, H.-O. Sjögren, T. Kalland, B. Widegren, and M. Dohlsten. 1996. Fusion of a signal sequence to the interleukin-1 β gene directs the protein from cytoplasmic accumulation to extracellular release. *Cell Immunol.* 169: 226–237.
- Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. *J. Immunol.* 174: 636–645.
- Zar, J. H. 1999. *Biostatistical Analysis*. Prentice-Hall, Upper Saddle River, NJ.
- Simms, E. L., and D. S. Burdick. 1988. Profile analysis of variance as a tool for analyzing correlated responses in experimental ecology. *Biometrical Journal* 30: 229–242.
- Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunosurveillance: from immunosurveillance to tumor escape. *Nat. Immunol.* 3: 991–998.
- Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunosurveillance. *Immunity* 21: 137–148.
- Blaser, M. J., P. H. Chyou, and A. Nomura. 1995. Age at establishment of *Helicobacter pylori* infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. *Cancer Res.* 55: 562–565.
- Ernst, P. B., and B. D. Gold. 2000. The disease spectrum of *Helicobacter pylori*: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. *Annu. Rev. Microbiol.* 54: 615–640.
- Björkdahl, O., M. Dohlsten, and H.-O. Sjögren. 2000. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1 β induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. *Cancer Gene Ther.* 7: 1365–1374.
- Björkdahl, O., A. G. Wingren, G. Hedlund, L. Ohlsson, and M. Dohlsten. 1997. Gene transfer of a hybrid interleukin-1 β gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo. *Cancer Immunol. Immunother.* 46: 273–281.
- Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. *Blood* 87: 2095–2147.
- Kusmartsev, S., Y. Nefedova, D. Yoder, and D. I. Gabrilovich. 2004. Antigen-specific inhibition of CD8⁺ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. *J. Immunol.* 172: 989–999.
- Mazzoni, A., V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanoello, and D. M. Segal. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. *J. Immunol.* 168: 689–695.
- Huang, Q., J. Yang, Y. Lin, C. Walker, J. Cheng, Z. G. Liu, and B. Su. 2004. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEK3. *Nat. Immunol.* 5: 98–103.
- Muroi, M., T. Ohnishi, and K. Tanamoto. 2002. Regions of the mouse CD14 molecule required for Toll-like receptor 2- and 4-mediated activation of NF- κ B. *J. Biol. Chem.* 277: 42372–42379.
- Danna, E. A., P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg. 2004. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. *Cancer Res.* 64: 2205–2211.